MedPath

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Phase 1
Active, not recruiting
Conditions
Neoplasm
Cancer
Interventions
Registration Number
NCT04717375
Lead Sponsor
Sanofi
Brief Summary

The study will enroll advanced cancer patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy. The study will be comprised of two parts - a dose escalation phase (Part 1) and a dose optimization/expansion phase (Part 2). Part 1 is comprised of three sub-parts: SAR444881 administered alone (Sub-Part 1A), SAR444881 administered in combination with pembrolizumab (Sub-Part 1B), and SAR444881 administered in combination with cetuximab (Sub-Part 1C). Part 2 is composed of two sub-parts: a dose optimization part where up to two doses of SAR444881 per indication are administered in combination with pembrolizumab, cetuximab, and/or carboplatin and pemetrexed (Sub-Part 2A); and a dose expansion part where SAR444881 is administered alone (Sub-Part 2B). In Sub-Part 2A, a two-stage design will be implemented to conduct dose optimization for each indication with combination therapy- Stage 1 (Preliminary Assessment) and Stage 2 (Randomization). Study is non-randomized except Stage 2 of Sub-Part 2A which will use randomization.

Detailed Description

Estimated Study Duration:

Dose Escalation (Part 1): Approximately 34 months Dose Optimization/Expansion (Part 2): Approximately 28 months

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
456
Inclusion Criteria
  • Patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy
  • Histologic confirmation of malignancy
  • Measurable disease per RECIST v1.1
  • Eastern Cooperative Oncology Group Performance Status (ECOG) of 0 or 1
  • Participants must have adequate organ function as defined by laboratory tests
  • Part 1: Following tumor types: Breast cancer, cervical cancer, colorectal cancer, adenocarcinoma or squamous cell carcinoma of the esophagus, gastric or gastroesophageal junction adenocarcinoma, squamous cell carcinoma of the head and neck, hepatobiliary cancers (hepatocellular carcinoma (HCC), gallbladder cancer, cholangiocarcinoma), non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the skin, pancreatic adenocarcinoma, ovarian cancer or urothelial carcinoma
  • Part 2: Following tumor types: Squamous cell carcinoma of the head and neck, Gastric or gastroesophageal junction adenocarcinoma, non-squamous non-small cell lung cancer, non-small cell lung cancer, colorectal carcinoma (CRC) any RAS, and/or Cholangiocarcinoma
Exclusion Criteria
  • Active, known or suspected autoimmune disease
  • Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
  • Brain or leptomeningeal metastases
  • Known history of positive test for HIV
  • Non-HCC patients: acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV); HCC patients: untreated active HBV or dual infection with HBV/HCV
  • Participants after solid organ or allogeneic hematopoietic stem cell transplant
  • History of life-threatening toxicity related to prior immune therapy
  • History of life-threatening toxicity related to prior cetuximab or other anti-EGFR antibodies (for Sub-Part 1C)
  • Unstable or deteriorating cardiovascular disease within the previous 6 months
  • Any major surgery within 4 weeks of study drug administration
  • Prior/Concomitant Therapy:
  • Cytotoxic/Non-cytotoxic anti-cancer agents, unless at least 4 weeks have elapsed from last dose
  • Use of other investigational drugs within 28 days
  • Prior treatment with macrophage or natural killer (NK) cells activating therapies
  • Administration of a live attenuated vaccine within 28 days

The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
SAR444881 Dose Escalation (Sub-Part 1A)SAR444881Standard "3 + 3" dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 will be administered intravenously (IV), every 2 weeks (Q2W).
SAR444881 in Combination with Pembrolizumab Dose Escalation (Sub-Part 1B)SAR444881Standard "3 + 3" dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 and pembrolizumab will be administered intravenously (IV), every 3 weeks (Q3W).
SAR444881 Dose Expansion (Sub-Part 2B)SAR444881The indication for this monotherapy cohort is cholangiocarcinoma. Enrollment will be opened based on emerging data from the dose-escalation phase and combination optimization data.
SAR444881 in Combination with Cetuximab Dose Escalation (Sub-Part 1C)SAR444881Standard "3 + 3" dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 and cetuximab will be administered intravenously (IV), every 2 weeks (Q2W).
SAR444881 Dose Optimization (Sub-Part 2A)SAR444881SAR444881 Dose Optimization in combination with pembrolizumab/carboplatin/pemetrexed, pembrolizumab, or cetuximab. The indication for the combination cohorts will be non-squamous non-small cell lung cancer (NSCLC), gastric cancer or gastro-esophageal junction adenocarcinoma (GC/GEJ), colorectal carcinoma (CRC) any RAS. Enrollment will start after the recommended dose(s) of SAR444881 have been determined based on data from Sub-Parts 1A, 1B, and 1C.
SAR444881 in Combination with Pembrolizumab Dose Escalation (Sub-Part 1B)PembrolizumabStandard "3 + 3" dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 and pembrolizumab will be administered intravenously (IV), every 3 weeks (Q3W).
SAR444881 in Combination with Cetuximab Dose Escalation (Sub-Part 1C)CetuximabStandard "3 + 3" dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 and cetuximab will be administered intravenously (IV), every 2 weeks (Q2W).
SAR444881 Dose Optimization (Sub-Part 2A)CetuximabSAR444881 Dose Optimization in combination with pembrolizumab/carboplatin/pemetrexed, pembrolizumab, or cetuximab. The indication for the combination cohorts will be non-squamous non-small cell lung cancer (NSCLC), gastric cancer or gastro-esophageal junction adenocarcinoma (GC/GEJ), colorectal carcinoma (CRC) any RAS. Enrollment will start after the recommended dose(s) of SAR444881 have been determined based on data from Sub-Parts 1A, 1B, and 1C.
SAR444881 Dose Optimization (Sub-Part 2A)CarboplatinSAR444881 Dose Optimization in combination with pembrolizumab/carboplatin/pemetrexed, pembrolizumab, or cetuximab. The indication for the combination cohorts will be non-squamous non-small cell lung cancer (NSCLC), gastric cancer or gastro-esophageal junction adenocarcinoma (GC/GEJ), colorectal carcinoma (CRC) any RAS. Enrollment will start after the recommended dose(s) of SAR444881 have been determined based on data from Sub-Parts 1A, 1B, and 1C.
SAR444881 Dose Optimization (Sub-Part 2A)PembrolizumabSAR444881 Dose Optimization in combination with pembrolizumab/carboplatin/pemetrexed, pembrolizumab, or cetuximab. The indication for the combination cohorts will be non-squamous non-small cell lung cancer (NSCLC), gastric cancer or gastro-esophageal junction adenocarcinoma (GC/GEJ), colorectal carcinoma (CRC) any RAS. Enrollment will start after the recommended dose(s) of SAR444881 have been determined based on data from Sub-Parts 1A, 1B, and 1C.
SAR444881 Dose Optimization (Sub-Part 2A)PemetrexedSAR444881 Dose Optimization in combination with pembrolizumab/carboplatin/pemetrexed, pembrolizumab, or cetuximab. The indication for the combination cohorts will be non-squamous non-small cell lung cancer (NSCLC), gastric cancer or gastro-esophageal junction adenocarcinoma (GC/GEJ), colorectal carcinoma (CRC) any RAS. Enrollment will start after the recommended dose(s) of SAR444881 have been determined based on data from Sub-Parts 1A, 1B, and 1C.
Primary Outcome Measures
NameTimeMethod
Part 1: Incidence of treatment-emergent adverse events and serious adverse eventsThrough study completion, an average of 5 months
Part 1: Incidence of treatment-emergent adverse events (TEAEs) dose limiting toxicities (DLT)Cycle 1 (28 days)

Incidence of TEAEs meeting protocol defined DLT criteria

Part 2: Objective Response Rate (ORR) per RECIST v1.1Through study completion, an average of 3 months

Proportion of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1

Secondary Outcome Measures
NameTimeMethod
Part 2: Incidence of treatment-emergent adverse events and Serious Adverse EventsThrough study completion, an average of 6 months
Part 1: Incidence of anti-drug antibodies (ADA)Through study completion, an average of 5 months
Part 1: Serum concentration at the end of the dosing interval (Ctrough)Through study completion, an average of 2 months
Part 1: Objective Response Rate (ORR) per RECIST v1.1Through study completion, an average of 3 months

Proportion of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1

Part 1: Terminal elimination half-life [T1/2]Through study completion, an average of 2 months
Part 1: Area under the plasma concentration-time curve [AUC]Through study completion, an average of 2 months
Part 2: Progression Free Survival (PFS)Up to 24 months

Time from the date of first dose of study drug to the date of first documented disease progression or death due to any cause, whichever occurs first.

Part 2: CtroughThrough study completion, an average of 3 months
Part 1: Maximum observed plasma concentration [Cmax]Through study completion, an average of 2 months
Part 1: time of maximum observed serum concentration (Tmax)Through study completion, an average of 2 months
PFS rateAt 3, 6, 9, and 12 months, and up to 24 months

Percentage of participants with PFS, per RECIST v1.1

Part 2: AUCThrough study completion, an average of 3 months
Part 2: Duration of ResponseThrough study completion, an average of 6 months

Duration between first documentation of CR or PR to first documentation of disease progression or death due to any cause, whichever occurs first

Part 2: CmaxThrough study completion, an average of 3 months
Part 2: TmaxThrough study completion, an average of 3 months
Part 2: T1/2Through study completion, an average of 3 months
Part 2: Incidence of ADAThrough study completion, an average of 6 months

Trial Locations

Locations (18)

Investigational Site Number : 3760005

🇮🇱

Jerusalem, Israel

Investigational Site Number : 3760001

🇮🇱

Petah Tikva, Israel

Investigational Site Number : 3760003

🇮🇱

Ramat Gan, Israel

Investigational Site Number : 3760002

🇮🇱

Tel Aviv, Israel

Investigational Site Number : 8260003

🇬🇧

London, London, City Of, United Kingdom

Investigational Site Number : 8260002

🇬🇧

Leeds, United Kingdom

Mayo Clinic Hospital- Site Number : 8400003

🇺🇸

Phoenix, Arizona, United States

City of Hope Comprehensive Cancer Center- Site Number : 8400002

🇺🇸

Duarte, California, United States

University of Colorado- Site Number : 8400012

🇺🇸

Aurora, Colorado, United States

Smilow Cancer Center at Yale-New Haven- Site Number : 8400001

🇺🇸

New Haven, Connecticut, United States

Clermont Oncology Center- Site Number : 8400005

🇺🇸

Clermont, Florida, United States

Mid Florida Hematology and Oncology Center- Site Number : 8400006

🇺🇸

Orange City, Florida, United States

Mercy Cancer Center - MercyOne Richard Deming Cancer Center- Site Number : 8400011

🇺🇸

Des Moines, Iowa, United States

Norton Cancer Institute - Downtown Women's Cancer Center- Site Number : 8400004

🇺🇸

Louisville, Kentucky, United States

Mayo Clinic Hospital Rochester- Site Number : 8400007

🇺🇸

Rochester, Minnesota, United States

Investigational Site Number : 1240001

🇨🇦

Barrie, Ontario, Canada

Investigational Site Number : 1240003

🇨🇦

Sherbrooke, Quebec, Canada

Investigational Site Number : 3760004

🇮🇱

Haifa, Israel

© Copyright 2025. All Rights Reserved by MedPath